May 24, 2018
Basilea Pharmaceutica: Subscription to Basilea's Press Release Newsletter
Dear Subscriber to the Basilea Press Release Newsletter
You receive this e-mail because you subscribed to Basilea's press release newsletter. With the new EU General Data Protection Regulation (GDPR) coming into force on May 25, 2018, we want to inform you how the personal data you provided when you subscribed for the newsletter is processed by Basilea Pharmaceutica Ltd. through its wholly owned subsidiary Basilea Pharmaceutica International Ltd.
During the registration process for our newsletter we collected the name, the e-mail address, the company/organization, the classification (e.g. institutional investor, private investor, etc.), and the country that you provided. We will use your e-mail address only to send you Basilea's press releases by e-mail. You can revoke your consent to receive the press releases at any time and unsubscribe from the newsletter anytime by clicking on the unsubscribe link provided in every newsletter e-mail, on our website at www.basilea.com/Investor-Relations/News-subscription/, or by e-mail by answering to this e-mail. Your personal data will be deleted as soon as they are no longer necessary to achieve the purpose for which they were collected. Therefore, your e-mail address and other personal data will be stored as long as your subscription to the newsletter will be active.
Basilea Pharmaceutica International Ltd.
For further information, please contact:
| Peer Nils Schröder, PhD |
Head of Corporate Communications & Investor Relations
+41 61 606 1102